CoChat

Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance

Open access
Fleming-Dutra, Katherine E., Britton, Amadea, Shang, Nong, Derado, Gordana, Link-Gelles, Ruth, Accorsi, Emma K., Smith, Zachary R., Miller, Joseph, Verani, Jennifer R., Schrag, Stephanie J. · 2022 · JAMA
Cited by 149

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Importance: Efficacy of 2 doses of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech) against COVID-19 was high in pediatric trials conducted before the SARS-CoV-2 Omicron variant emerged. Among adults, estimated vaccine effectiveness (VE) of 2 BNT162b2 doses against symptomatic Omicron infection was reduced compared with prior variants, waned rapidly, and increased with a booster. Objective: To evaluate the association of symptomatic infection with prior vaccination with BNT162b2 to estimate VE among children and adolescents during Omicron variant predominance. Design, Setting, and Participants: A test-negative, case-control analysis was conducted using data from 6897 pharmacy-based, drive-through SARS-CoV-2 testing sites across the US from a single pharmacy chain in the Increasing Community Access to Testing platform. This analysis included 74 208 tests from children 5 to 11 years of age and 47 744 tests from adolescents 12 to 15 years of age with COVID-19-like illness who underwent SARS-CoV-2 nucleic acid amplification testing from December 26, 2021, to February 21, 2022. Exposures: Two BNT162b2 doses 2 weeks or more before SARS-CoV-2 testing vs no vaccination for children; 2 or 3 doses 2 weeks or more before testing vs no vaccination for adolescents (who are recommended to receive a booster dose). Main Outcomes and Measures: Symptomatic infection. The adjusted odds ratio (OR) for the association of prior vaccination and symptomatic SARS-CoV-2 infection was used to estimate VE: VE = (1 - OR) × 100%. Results: A total of 30 999 test-positive cases and 43 209 test-negative controls were included from children 5 to 11 years of age, as well as 22 273 test-positive cases and 25 471 test-negative controls from adolescents 12 to 15 years of age. The median age among those with included tests was 10 years (IQR, 7-13); 61 189 (50.2%) were female, 75 758 (70.1%) were White, and 29 034 (25.7%) were Hispanic/Latino. At 2 to 4 weeks after dose 2, among children, the adjusted OR was 0.40 (95% CI, 0.35-0.45; estimated VE, 60.1% [95% CI, 54.7%-64.8%]) and among adolescents, the OR was 0.40 (95% CI, 0.29-0.56; estimated VE, 59.5% [95% CI, 44.3%-70.6%]). During month 2 after dose 2, among children, the OR was 0.71 (95% CI, 0.67-0.76; estimated VE, 28.9% [95% CI, 24.5%-33.1%]) and among adolescents, the OR was 0.83 (95% CI, 0.76-0.92; estimated VE, 16.6% [95% CI, 8.1%-24.3%]). Among adolescents, the booster dose OR 2 to 6.5 weeks after the dose was 0.29 (95% CI, 0.24-0.35; estimated VE, 71.1% [95% CI, 65.5%-75.7%]). Conclusions and Relevance: Among children and adolescents, estimated VE for 2 doses of BNT162b2 against symptomatic infection was modest and decreased rapidly. Among adolescents, the estimated effectiveness increased after a booster dose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2022.7493

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 10

  1. Marks, 2022, Hospitalizations of children and adolescents with laboratory-confirmed COVID-19: COVID-NET, 14 states, July 2021-January 2022., MMWR Morb Mortal Wkly Rep, 71, 271, 10.15585/mmwr.mm7107e4 · DOI · Paper page
  2. Britton, 2022, Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance., JAMA, 327, 1032, 10.1001/jama.2022.2068 · DOI
  3. Miller, 2021, Community-based testing sites for SARS-CoV-2: United States, March 2020-November 2021., MMWR Morb Mortal Wkly Rep, 70, 1706, 10.15585/mmwr.mm7049a3 · DOI
  4. Chua, 2020, The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology., Epidemiology, 31, 43, 10.1097/EDE.0000000000001116 · DOI · Paper page
  5. Wallace, 2021, The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years: United States, May 2021., MMWR Morb Mortal Wkly Rep, 70, 749, 10.15585/mmwr.mm7020e1 · DOI · Paper page
  6. Woodworth, 2021, The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years: United States, November 2021., MMWR Morb Mortal Wkly Rep, 70, 1579, 10.15585/mmwr.mm7045e1 · DOI · Paper page
  7. Klein, 2022, Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years: VISION Network, 10 states, April 2021-January 2022., MMWR Morb Mortal Wkly Rep, 71, 352, 10.15585/mmwr.mm7109e3 · DOI · Paper page
  8. Fowlkes, 2022, Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years: PROTECT cohort, July 2021-February 2022., MMWR Morb Mortal Wkly Rep, 71, 422, 10.15585/mmwr.mm7111e1 · DOI · Paper page
  9. Jackson, 2015, Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness., Vaccine, 33, 1313, 10.1016/j.vaccine.2015.01.069 · DOI
  10. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2, the virus that causes COVID-19. Accessed March 10, 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html · DOI · Paper page

Cited by

See all 149

Metadata

Authors
Fleming-Dutra, K. E., Britton, A., Shang, N., Derado, G., Link-Gelles, R., Accorsi, E. K., Smith, Z. R., Miller, J., Verani, J. R., & Schrag, S. J.
Venue
JAMA
Published
2022-06-14
Volume
327
Issue
22
Pages
2210
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4280551210
Cited by
149
References
6
FWCI
16.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.